Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/13967
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | DELVA, Wim | - |
dc.contributor.author | Eaton, Jeffrey W. | - |
dc.contributor.author | MENG, Fei | - |
dc.contributor.author | Fraser, Christophe | - |
dc.contributor.author | White, Richard G. | - |
dc.contributor.author | Vickerman, Peter | - |
dc.contributor.author | Boily, Marie-Claude | - |
dc.contributor.author | Hallett, Timothy B. | - |
dc.date.accessioned | 2012-09-07T12:13:46Z | - |
dc.date.available | 2012-09-07T12:13:46Z | - |
dc.date.issued | 2012 | - |
dc.identifier.citation | PLOS MEDICINE, 9 (7), p. e1001258 | - |
dc.identifier.issn | 1549-1676 | - |
dc.identifier.uri | http://hdl.handle.net/1942/13967 | - |
dc.description.abstract | Until now, decisions about how to allocate ART have largely been based on maximising the therapeutic benefit of ART for patients. Since the results of the HPTN 052 study showed efficacy of antiretroviral therapy (ART) in preventing HIV transmission, there has been increased interest in the benefits of ART not only as treatment, but also in prevention. Resources for expanding ART in the short term may be limited, so the question is how to generate the most prevention benefit from realistic potential increases in the availability of ART. Although not a formal systematic review, here we review different ways in which access to ART could be expanded by prioritising access to particular groups based on clinical or behavioural factors. For each group we consider (i) the clinical and epidemiological benefits, (ii) the potential feasibility, acceptability, and equity, and (iii) the affordability and cost-effectiveness of prioritising ART access for that group. In re-evaluating the allocation of ART in light of the new data about ART preventing transmission, the goal should be to create policies that maximise epidemiological and clinical benefit while still being feasible, affordable, acceptable, and equitable. | - |
dc.description.sponsorship | WD thanks the Canadian International Development Agency (CIDA), the Flemish Interuniversity Council (VLIR), and the Flemish Scientific Research Fund (FWO) for funding support. FM was funded by the Flemish Scientific Research Fund (FWO). TBH thanks the Bill & Melinda Gates Foundation for funding support. RGW was funded by Medical Research Council (UK) Methodology Research Fellowship (G0802414) and the Consortium to Respond Effectively to the AIDS/TB Epidemic, funded by the Bill & Melinda Gates Foundation (19790.01). PV was funded by the Bill & Melinda Gates Foundation, Medical Research Council, and the World Bank. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. | - |
dc.language.iso | en | - |
dc.publisher | PUBLIC LIBRARY SCIENCE | - |
dc.subject.other | Medicine, General & Internal | - |
dc.title | HIV Treatment as Prevention: Optimising the Impact of Expanded HIV Treatment Programmes | - |
dc.type | Journal Contribution | - |
dc.identifier.issue | 7 | - |
dc.identifier.spage | e1001258 | - |
dc.identifier.volume | 9 | - |
local.format.pages | 12 | - |
local.bibliographicCitation.jcat | A1 | - |
dc.description.notes | [Delva, Wim] Univ Stellenbosch, Natl Res Fdn, Ctr Excellence Epidemiol Modelling & Anal, S African Dept Sci & Technol, ZA-7600 Stellenbosch, South Africa. [Delva, Wim; Meng, Fei] Univ Ghent, Int Ctr Reprod Hlth, B-9000 Ghent, Belgium. [Eaton, Jeffrey W.; Fraser, Christophe; Boily, Marie-Claude; Hallett, Timothy B.] Univ London Imperial Coll Sci Technol & Med, Dept Infect Dis Epidemiol, London, England. [Meng, Fei] Hasselt Univ, Ctr Stat, Diepenbeek, Belgium. [White, Richard G.] Univ London London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, London WC1E 7HT, England. [Vickerman, Peter] Univ London London Sch Hyg & Trop Med, Dept Global Hlth & Dev, London WC1E 7HT, England. Wim.Delva@ugent.be | - |
local.publisher.place | SAN FRANCISCO | - |
local.type.refereed | Refereed | - |
local.type.specified | Review | - |
dc.bibliographicCitation.oldjcat | A1 | - |
dc.identifier.doi | 10.1371/journal.pmed.1001258 | - |
dc.identifier.isi | 000307106400014 | - |
item.fullcitation | DELVA, Wim; Eaton, Jeffrey W.; MENG, Fei; Fraser, Christophe; White, Richard G.; Vickerman, Peter; Boily, Marie-Claude & Hallett, Timothy B. (2012) HIV Treatment as Prevention: Optimising the Impact of Expanded HIV Treatment Programmes. In: PLOS MEDICINE, 9 (7), p. e1001258. | - |
item.fulltext | With Fulltext | - |
item.validation | ecoom 2013 | - |
item.contributor | DELVA, Wim | - |
item.contributor | Eaton, Jeffrey W. | - |
item.contributor | MENG, Fei | - |
item.contributor | Fraser, Christophe | - |
item.contributor | White, Richard G. | - |
item.contributor | Vickerman, Peter | - |
item.contributor | Boily, Marie-Claude | - |
item.contributor | Hallett, Timothy B. | - |
item.accessRights | Open Access | - |
crisitem.journal.issn | 1549-1277 | - |
crisitem.journal.eissn | 1549-1676 | - |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
HIV treatment as prevention.pdf | Published version | 304.06 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.